



TANDEM DIABETES CARE

Control IQ+ Technology

Meet the New
Standard of Care




Heena
diagnosed 2021

Afsha
diagnosed 2000



Agenda


- + Introduction to diabetes technology
- + Control-IQ+ technology
- + Support and training
- + How to check your benefits
- + Questions



Iliani
diagnosed 2001




Introduction to Diabetes Technology



This is one month worth of shots for a type 1 diabetic.



Americans with diabetes.
This is **11.6% of the population**, or almost the population of Canada.¹



Americans living with type 2 diabetes, with **about 12.3% of patients diagnosed with diabetes start insulin within one year of diagnosis.**²



Americans living with type 1 diabetes, which is around **5.7% of all diabetes cases** (population of Houston, TX).¹




Prevalence of Diabetes & Pump Therapy

¹ National Diabetes Statistics Report. Centers for Disease Control and Prevention. <https://www.cdc.gov/diabetes/php/data-research/index.html>. Published May 15, 2024. Accessed August 25, 2025.

² Type 2 Diabetes. Centers for Disease Control and Prevention. <https://www.cdc.gov/diabetes/php/data-research/index.html>. Published May 15, 2024. Accessed August 28, 2025.

Advances in Diabetes Technology Provide Better Outcomes, Yet Utilization Remains Low

Change in Percentage of Diabetes Technology Users and Change in A1c¹



Studies with various automated insulin delivery (AID) systems demonstrate improvement in glycemic outcomes,² yet:



of people living with type 1 diabetes
use an AID system³



42

Factors that affect Blood Glucose

FOOD



- ↑↑ 1 Carbohydrate quantity
- ↑ 2 Carbohydrate type
- ↑ 3 Fat
- ↑ 4 Protein
- ↑ 5 Caffeine
- ↓↑ 6 Alcohol
- ↓↑ 7 Meal timing
- ↑ 8 Dehydration
- ? 9 Personal microbiome

MEDICATION



- ↓ 10 Medication dose
- ↓↑ 11 Medication timing
- ↓↑ 12 Medication interactions
- ↑↑ 13 Steroid administration
- ↑ 14 Niacin (Vitamin B3)

BIOLOGICAL



- ↑ 20 Too little sleep
- ↑ 21 Stress and illness
- ↓ 22 Recent hypoglycemia
- ↑ 23 During-sleep blood sugars
- ↑ 24 Dawn phenomenon
- ↑ 25 Infusion set issues
- ↑ 26 Scar tissue / lipodystrophy
- ↓↓ 27 Intramuscular insulin delivery
- ↑ 28 Allergies
- ↑ 29 A higher BG level (glucotoxicity)
- ↓↑ 30 Periods (menstruation)
- ↑↑ 31 Puberty
- ↓↑ 32 Celiac disease
- ↑ 33 Smoking

ACTIVITY



- ↓ 15 Light exercise
- ↓↑ 16 High-intensity & moderate exercise
- ↓ 17 Level of fitness/training
- ↓↑ 18 Time of day
- ↓↑ 19 Food and insulin timing

The arrows show the general effect these 42 factors seem to have on blood glucose based on scientific research and/or our experiences at diaTribe. However, not every individual will respond in the same way, so the best way to see how a factor affects you is through your own data; check your blood glucose more often with a meter or wear a CGM and look for patterns.

ENVIRONMENTAL



- ↑ 34 Expired insulin
- ↓↑ 35 Inaccurate BG reading
- ↓↑ 36 Outside temperature
- ↑ 37 Sunburn
- ? 38 Altitude

BEHAVIOR & DECISIONS

- ↓ 39 More frequent BG checks
- ↓↑ 40 Default options and choices
- ↓↑ 41 Decision-making biases
- ↓↑ 42 Family and social pressures


diaTribe

Read more about the 42 Factors at diaTribe.org/42FactorsExplained
Sign up for diaTribe's updates at diaTribe.org/Join




The Many Faces of 7% HbA1c

TIME IN RANGE (TIR) (70-180 MG/DL) IS IMPORTANT TO REDUCE GLYCEMIC VARIABILITY



2025 STANDARDS OF CARE IN DIABETES¹

CGM Metrics Inform a Personalized Diabetes Management Plan



54%
of people
living with
type 1 diabetes
are
**not meeting
TIR goals²**

* Includes percentage of values >250 mg/dL † Includes percentage of values <54 mg/dL
1. Diabetes Technology: Standards of Care in Diabetes - 2025. Diabetes Care. 2025;48(Suppl. 1):S146-S166.
2. Calhoun, P, et al. Diabetes Technol Ther. 2021;23(3): 230-233. doi: 10.1089/dia.2020.0471.



Exogenous Insulin Regimens

Fixed dose or sliding scale:

- + Set amounts of insulin 1-3 times/day

Intensive insulin:

- + Multiple daily injections (“intensive insulin”)
- + Long-acting basal insulin
(e.g., glargine, degludec)
- + Rapid-acting insulin for boluses
(e.g., aspart, lispro, glulisine)

Insulin pumps:

- + Rapid-acting insulin infused as basal/
bolus therapy





Adhesive sleeve sold separately.

DIABETES MANAGEMENT IS
CONTINUOUS AND PERSONAL

Evolution of Insulin Pump Therapy

Today, using automated insulin delivery (AID) systems like Control-IQ+ technology can improve time in range, reduce burden of management, and improve the patient's satisfaction with diabetes self-management.



Adhesive sleeve sold separately.

Remember that iconic picture of Dr. Arnold Kadish carrying an insulin pump as a backpack? It's incredible how much diabetes management has evolved since then.


CGM + Insulin Pump + Algorithm = AID

AID Definition:

- + Insulin pump with integrated CGM and an algorithm that automatically calculates partial or full insulin delivery in real time
- + Ultimately targeting a glucose value and giving insulin based off CGM readings

AID Benefits:

- + Freedom from injections
- + Perfect behavior is not required
- + Spontaneous living is possible again!



Which pump is right for your patient?

* Future updates for all or some Tandem products may not be developed and may not be offered everywhere and would be subject to applicable regulatory approvals. Software updates are only available to customers who are in warranty at the time they update their pump. Additional training may be required to access certain software updates. Charges may apply. Tandem may discontinue select software and features over time at its discretion. † Adhesive sleeve sold separately. ‡ Our mobile apps require a compatible [smartphone model and operating system](#) (sold separately). For t:slim X2 insulin pump users bolus delivery also requires an app update, a remote software update on the pump, and additional training. § CGM sensors sold separately.

© 2025 Tandem Diabetes Care, Inc. All Rights Reserved

BUILT FOR ALL LIFESTYLES

- Control-IQ+ Technology
- ≥2 years old for type 1
 - ≥18 years old for type 2

Remote Software Updates*

On-Body Wear†

Smartphone Control‡

Smartphone Compatibility

Insulin Capacity

Integrated Color Touchscreen

Dexcom G6 and G7 Integration§

FreeStyle Libre 2 Plus Integration§

Pump Button for Bolus Delivery

Tandem
Mobi

t:slim X2



Mobile Bolus Only

iOS

iOS & Android

200 units

300 units



CONTROL-IQ+

Control-IQ+ Technology Works Every 5 Minutes


Dynamic 5-minute adjustments

From zero to ~4x the programmed basal rate



Only System with AutoBolus

To help with missed meal boluses and prevent hyperglycemia



Decreases or stops basal insulin if sensor glucose is predicted to be low



Increases basal insulin and delivers AutoBolus* (💧) if sensor glucose is predicted to be high



HOW IT WORKS: AUTOBOLUS

AutoBolus


- When predicted to be greater than 180 mg/dL
- Up to once per hour
- Delivers 60% calculated dose



Time in Range

Past 24 hr (70-180 mg/dL)

85%



Support and Training for Patients



TANDEM PATIENT JOURNEY

Training and Education Experience



A BOLUS OF BENEFITS

The Support
You Need,
When You
Need It



Expert Training



24/7 Customer Support



Local Certified Trainers




Dedicated HCP Support Line



How to Start the Referral Process

TandemDiabetes.com



Stephanie: (509) 860-0871




SIMULATORS

Hands-On Experience with Tandem Products


T:SLIM X2 PUMP

Download the t:simulator app* on your compatible smartphone and experience the easy-to-use interface of the t:slim X2 pump.



TANDEM MOBI

Test drive the easy-to-use Tandem Mobi mobile app simulator on our website, without needing to download an app.



tandemdiabetes.com/mobi-simulator



Questions



Important Safety Information

RX ONLY.

Tandem Mobi system: The Tandem Mobi insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.

t:slim X2 insulin pump: The t:slim X2 insulin pump with interoperable technology (the pump) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. The pump is indicated for use in persons 2 years of age and greater.

Control-IQ+ technology: Control-IQ+ technology is intended for use with compatible integrated continuous glucose monitors (iCGM, sold separately) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and suspend delivery of basal insulin based on iCGM readings and predicted glucose values. It can also deliver correction boluses when the glucose value is predicted to exceed a predefined threshold. Control-IQ+ technology is intended for the management of type 1 diabetes mellitus in persons 2 years of age and greater and of type 2 diabetes mellitus in persons 18 years of age and greater.

WARNING: Control-IQ+ technology should not be used in anyone under the age of 2 years old with type 1 diabetes or under the age of 18 years old with type 2 diabetes. It should also not be used in patients who require less than a total daily insulin dose of 5 units of insulin per day or who weigh less than 20 pounds (9 kilograms), as those are the required minimum values needed for Control-IQ+ to operate safely.

Users of the pump and Control-IQ+ must: use the insulin pump, iCGM, and all other system components in accordance with their respective instructions for use. Failure to follow these instructions for use could result in an over delivery or under delivery of insulin. This can cause hypoglycemia (low BG) or hyperglycemia (high BG) events. Visit tandemdiabetes.com/safetyinfo for additional important safety information.



Tandem t:slim mobile app: The feature set available within the Tandem t:slim mobile app is dependent on the pump software version and the compatible smartphone's model and operating system (OS).

- The **Display and Data Upload** feature set provides a secondary display of pump and continuous glucose monitoring (CGM) information, including display of your pump alerts and alarms, and enables wireless uploading of pump and CGM data to the Tandem cloud through an internet or wireless data connection. Standard carrier data rates may apply.
- The **Bolus Delivery plus Display and Data Upload** feature set additionally allows users to request, stop, and cancel a bolus on the pump from the Tandem t:slim mobile app. At least one smartphone security setting must be enabled to utilize the Bolus Delivery feature of the Tandem t:slim mobile app.
- **WARNING:** Always rely on your pump to make therapy decisions when using a smartphone that is incompatible with the Bolus Delivery feature.
- **PRECAUTIONS:** Always rely on your pump to make therapy decisions if using a smartphone that is incompatible, the smartphone is lost or damaged, or the smartphone loses *Bluetooth*® connectivity with your pump. Important pump alerts and alarms are only received as app notifications when enabled and the app is either active or running in the background.

The Tandem Source platform is intended for use by individuals with diabetes mellitus who use Tandem Diabetes Care insulin pumps, their caregivers, and their healthcare providers in home and clinical settings. The Tandem Source platform supports diabetes management through the display and analysis of information uploaded from Tandem insulin pumps.

©2025 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Tandem logos, Control-IQ, Control-IQ+, Tandem Mobi, t:slim, t:simulator, Tandem Source, and t:slim X2 are registered trademarks of Tandem Diabetes Care, Inc. in the United States and/or other countries. Dexcom, Dexcom G6, Dexcom G7, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott and used with permission. The Bluetooth® wordmark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Tandem Diabetes Care, Inc. is under license. Apple, the Apple logo, iPhone, iPad, and iPod are trademarks of Apple Inc., registered in the U.S. and other countries. App Store is a service mark of Apple Inc. iOS is a trademark or registered trademark of Cisco in the U.S. and other countries and is used under license. Google Play, the Google Play logo, and Android are trademarks of Google LLC. All third-party marks are the property of their respective owners. MAT-0818_1

